BR112018069507A2 - agentes de alta afinidade alvejados por antígeno de membrana específica da próstata para endoradioterapia de câncer de próstata - Google Patents
agentes de alta afinidade alvejados por antígeno de membrana específica da próstata para endoradioterapia de câncer de próstataInfo
- Publication number
- BR112018069507A2 BR112018069507A2 BR112018069507A BR112018069507A BR112018069507A2 BR 112018069507 A2 BR112018069507 A2 BR 112018069507A2 BR 112018069507 A BR112018069507 A BR 112018069507A BR 112018069507 A BR112018069507 A BR 112018069507A BR 112018069507 A2 BR112018069507 A2 BR 112018069507A2
- Authority
- BR
- Brazil
- Prior art keywords
- endoradotherapy
- prostate
- high affinity
- specific membrane
- targeted agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
agentes de alta afinidade alvejados por antígeno de membrana específica da próstata para endoradioterapia de câncer de próstata são revelados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662311697P | 2016-03-22 | 2016-03-22 | |
PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018069507A2 true BR112018069507A2 (pt) | 2019-01-29 |
Family
ID=59899817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018069507A BR112018069507A2 (pt) | 2016-03-22 | 2017-03-22 | agentes de alta afinidade alvejados por antígeno de membrana específica da próstata para endoradioterapia de câncer de próstata |
Country Status (27)
Country | Link |
---|---|
US (2) | US11458213B2 (pt) |
EP (2) | EP3433238B1 (pt) |
JP (3) | JP7073270B2 (pt) |
KR (3) | KR20220063298A (pt) |
CN (2) | CN109311827B (pt) |
AU (1) | AU2017238181B2 (pt) |
BR (1) | BR112018069507A2 (pt) |
CA (1) | CA3018709A1 (pt) |
CL (1) | CL2018002683A1 (pt) |
CY (1) | CY1124487T1 (pt) |
DK (2) | DK3925952T3 (pt) |
ES (1) | ES2877572T3 (pt) |
FI (1) | FI3925952T3 (pt) |
HR (2) | HRP20240215T1 (pt) |
HU (1) | HUE055607T2 (pt) |
LT (2) | LT3433238T (pt) |
MX (1) | MX2018011519A (pt) |
PH (1) | PH12018502048A1 (pt) |
PL (2) | PL3433238T3 (pt) |
PT (2) | PT3925952T (pt) |
RS (2) | RS65188B1 (pt) |
RU (2) | RU2021115958A (pt) |
SA (1) | SA518400103B1 (pt) |
SI (2) | SI3433238T1 (pt) |
TR (1) | TR201813644T1 (pt) |
WO (1) | WO2017165473A1 (pt) |
ZA (1) | ZA201806389B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019002560B1 (pt) | 2016-08-10 | 2022-08-16 | Cancer Targeted Technology Llc | Composto, composição farmacêutica, seus usos e método de preparação do mesmo |
BR112019010206A2 (pt) * | 2016-11-23 | 2019-09-03 | Cancer Targeted Tech Llc | composto, composição farmacêutica, e, método para formar imagem de uma ou mais células cancerígenas de próstata |
WO2018111989A1 (en) | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
EP3618867A4 (en) | 2017-05-02 | 2021-01-20 | Cornell University | METHODS AND REAGENTS FOR AGAINST TUMOR WITH HIGHER EFFICIENCY AND LOWER TOXICITY |
EP3630733A4 (en) * | 2017-05-30 | 2021-03-17 | The Johns Hopkins University | PROSTATE SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINE AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER |
EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
US11497819B2 (en) * | 2017-12-11 | 2022-11-15 | Technische Universität München | PSMA ligands for imaging and endoradiotherapy |
BR112020011789A2 (pt) * | 2017-12-13 | 2020-11-24 | Sciencons AS | complexo que compreende um composto de alvejamento de psma ligado a um radionuclídeo de chumbo ou tório |
SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
EA202091876A1 (ru) * | 2018-02-06 | 2020-12-10 | Дзе Джонс Хопкинс Юниверсити | Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака |
LT3778592T (lt) * | 2018-03-30 | 2023-06-26 | Futurechem Co., Ltd. | Psma veikiantys radioaktyvieji preparatai, skirti prostatos vėžio diagnozei ir gydymui |
EP3784294A4 (en) * | 2018-04-27 | 2022-01-05 | University of Iowa Research Foundation | COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES |
CN112770785A (zh) * | 2018-09-28 | 2021-05-07 | 海德堡大学 | 前列腺特异性膜抗原(psma)的标记抑制剂,其作为显像剂和药剂用于治疗表达psma的癌症的用途 |
RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
WO2021001362A1 (en) | 2019-07-02 | 2021-01-07 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
JP2022538478A (ja) | 2019-07-02 | 2022-09-02 | アドバンスド アクセラレーター アプリケーションズ(イタリー)エスアールエル | 前立腺特異的膜抗原(psma)リガンド及びその使用 |
RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
US20230330278A1 (en) | 2020-04-29 | 2023-10-19 | Novartis Ag | Methods for radiolabelling psma binding ligands and their kits |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
WO2022101352A1 (en) | 2020-11-12 | 2022-05-19 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
WO2022106633A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
EP4355376A1 (en) * | 2021-06-17 | 2024-04-24 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
WO2023152671A1 (en) | 2022-02-09 | 2023-08-17 | Novartis Ag | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044468B2 (en) * | 2007-06-26 | 2015-06-02 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents |
WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
WO2010065902A2 (en) * | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma |
HRP20221195T1 (hr) * | 2009-03-19 | 2022-12-09 | The Johns Hopkins University | Spojevi koji ciljaju psma i njihova uporaba |
AU2012294639B2 (en) * | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
EP2785712B1 (en) | 2011-11-30 | 2019-05-01 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
JP6468602B2 (ja) * | 2013-01-14 | 2019-02-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | トリアジン系放射性医薬品及び放射線造影剤 |
EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
MY194484A (en) * | 2013-10-18 | 2022-11-30 | Deutsches Krebsforsch | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer |
CN111285918A (zh) * | 2014-05-06 | 2020-06-16 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
US10112974B2 (en) | 2014-08-24 | 2018-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer |
US11420910B2 (en) * | 2014-10-30 | 2022-08-23 | Katholieke Universitet Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Application Discontinuation
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Application Discontinuation
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 MX MX2018011519A patent/MX2018011519A/es unknown
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en active Application Filing
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active IP Right Grant
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 CN CN202210306552.XA patent/CN114716387A/zh active Pending
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-08-31 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018069507A2 (pt) | agentes de alta afinidade alvejados por antígeno de membrana específica da próstata para endoradioterapia de câncer de próstata | |
BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
BR112018005937A2 (pt) | conjugados de oligonucleotídeo de afinidade e usos destes | |
BR112017023821A2 (pt) | moduladores de k-ras | |
EP3630733A4 (en) | PROSTATE SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINE AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER | |
CL2017003307A1 (es) | Sistema de administración dirigida de principio activo celular | |
CY1123716T1 (el) | Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη | |
BR112017004444A2 (pt) | novos anticorpos anti-mfi2 e métodos de uso | |
BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
CL2019001522A1 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. | |
CL2020002510A1 (es) | Radiofármaco dirigido a antígeno de membrana específico de próstata (psma) para diagnosticar y tratar el cáncer de próstata | |
BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
BR112018077458A2 (pt) | proteases aspárticas | |
EA201991370A1 (ru) | Методы лечения поликистозной болезни почек | |
BR112018012883A2 (pt) | novos anticorpos anti-upk1b e métodos de uso | |
BR112019004276A2 (pt) | métodos para o tratamento de câncer ovariano | |
AR110347A1 (es) | Anticuerpos anti-kremen2 y métodos para su uso | |
CL2019000701S1 (es) | Calefactor por inducción | |
TR201112564U (tr) | Ayarlı besimatik. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 257/02 , C07D 401/12 , A61K 51/04 Ipc: A61K 51/04 (2006.01), C07D 401/12 (2006.01), C07D |